Humanized antibodies against the β-amyloid peptide
US8323647B2 · kind B2 · utility
1Cited by
0References
39Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 15, 2008 |
| Grant date | Dec 4, 2012 |
| Priority date | — |
| Expiry date | Sep 15, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/622
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerization of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.